Chimeric Adenoviral Vectors with dsRNA TLR3 Agonist
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid-based adenoviral vaccines have low efficiency in eliciting an immune response, and existing adenoviral vectors require time-consuming development processes for protein purification and attenuation, necessitating the need for new vectors that can efficiently induce an immune response against specific antigens.
Innovation Solution
Development of chimeric adenoviral expression vectors incorporating a TLR-3 agonist, specifically heterologous dsRNA, combined with immunogenic polypeptides like HIV envelope or influenza HA, to enhance immune response through non-parenteral administration routes such as oral, intranasal, or mucosal delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If standard adenoviral vectors are used for vaccine delivery, then the manufacturing process is rapid and inexpensive, but the antigen-specific immune response efficiency is low
Solution Approach 1:
The patent creates a composite vaccine formulation by combining adenoviral vectors expressing antigen with dsRNA adjuvants. This composite approach enhances the immune response efficiency without compromising the rapid manufacturing capabilities of adenoviral systems, as the dsRNA component can be synthesized separately and combined with the viral vector
2Adaptability or versatility
If protein purification methods are developed for each new vaccine, then the vaccine can be customized for specific antigens, but the development process becomes extremely time-consuming
Solution Approach 1:
The patent replaces the mechanical/protein purification approach with a nucleic acid-based expression system. By using adenoviral vectors that express antigens directly from DNA/RNA sequences, the system eliminates time-consuming protein purification steps while maintaining the ability to customize vaccines for different antigens through simple nucleic acid sequence changes
3Adaptability or versatility
If attenuation methods are developed for live vaccines, then the pathogen growth is controlled for safety, but the complete attenuation process is extremely time-consuming
Solution Approach 1:
The patent extracts the replication competency from the adenoviral vector by deleting essential genes (E1, E2, E3, or E4 regions), creating replication-incompetent vectors. This extraction approach provides inherent safety control without requiring lengthy attenuation processes, as the vectors cannot replicate independently and require trans-complementation for propagation
4Productivity
If adenoviral vectors are administered to elicit immune response, then rapid vaccine development is achieved, but the antigen-specific response efficiency remains low
Solution Approach 1:
The patent introduces dsRNA as an intermediary adjuvant that mediates enhanced immune responses to the antigen expressed by the adenoviral vector. The dsRNA component acts as a bridge that amplifies the immunogenicity of the viral vector without interfering with the rapid development and manufacturing advantages of the adenoviral system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric adenoviral vectors significantly improve antigen-specific immune responses, as demonstrated by higher antibody titers and CD8+ T cell responses compared to standard adenoviral vectors, indicating enhanced immunogenicity and efficiency in vaccine delivery.
Implementation Method 1
a first promoter operably linked to a nucleic acid encoding a toll-like receptor (TLR)-3 agonist, wherein the TLR-3 agonist is heterologous dsRNA
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 2C
AI summary
The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.